Salute e Benessere

Turacoz Group bridging the gap between global and regional teams in medical…

Sharing the dais with Dr. Almudena Fraga, Director Global CX, Campaigns and Content in Marketing Operations, Lundbeck, Dr. Viraj Rajadhyaksha, Area Medical Director, AstraZeneca and Dr. Maged Saleh, Global BAVENCIO® Peer-to-Peer Marketing Lead, Merck, the panel discussed about the existing gaps between the global and local content creation teams, how these gaps can be better bridged by better collaboration, how the insights collected can be shared across teams to be integrated with the overall…

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics…

Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory Board, further strengthening support for the Company's long-term growth strategyNBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectivelyUpdate on expansion of product portfolio to include disruptive...

Canton Fair Hosts Industry Trend Forum on Home Furnishing and Market Strategy

The "Home Trends in 2025" report applies the STEPIC framework, covering six dimensions: society, technology, environment, politics, industry and creativity. This comprehensive analysis provides insights into market drivers and areas of innovation. The report paints a blueprint for the future of home living with sustainability, personalization and intelligence at its core, the trends of which not only shape the future direction of product design and interior design, but also have a…

ONWARD Medical Schedules Webcast to Provide Q3 2024 Update and Year-to-Date…

Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEA The webcast will be held on November 26, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q3 2024 and provide a business update.To join the webcast via Zoom, please register using thislink.Participants may also join by phone:+32 2 290 9360 (Belgium)+33 1 7095 0350 (France)...

World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)

(*) According to the Japan Patent Office's survey of global common awareness (Paragraph 1, Article 29, the Trademark Act) (*) According to the Japan Patent Office's survey of global common awareness (Paragraph 1, Article 29, the Trademark Act) Photo1: Patent recently acquired for Supplement Pinfenon (S) (R) series launched in 2004https://cdn.kyodonewsprwire.jp/prwfile/release/M103184/202410238652/_prw_PI1fl_5xfktVk4.jpg Mitral regurgitation, a cardiac disorder frequently observed in...

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European…

Saint-Herblain (France), November 12, 2024 –Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe.Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will host moderated “fireside chat” presentations to discuss the Company's key value drivers and...

Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with…

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program. The agreement enables ASTE, a pioneering healthcare distributor with over four decades of experience in Qatar, to address the high unmet need of DMD patients in the region. As the sole distributor of AGAMREE...

Perceptive eClinical Launches ClinPhone 5: A Ground-breaking new RTSM Platform…

Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new cloud native and multi-tenanted platform has been designed to accelerate the set-up and delivery of clinical trials, while also providing agility, adaptability, and scalability. Developed in partnership with CRScube, a renowned South Korean clinical research technology provider, the purpose-built new cloud native and multi-tenanted platform has been designed to…

Global D-Dimer Testing Market to Observe Growth at a CAGR of ~5% by 2030 |…

Key Takeaways from the D-Dimer Testing Market Report Key Takeaways from the D-Dimer Testing Market Report To read more about the latest highlights related to the D-dimer testing market, get a snapshot of the key highlights entailed in the Global D-Dimer Testing Market Report D-Dimer Testing Overview D-dimer testing is a blood test used to detect the presence of abnormal blood clotting, often aiding in the diagnosis of conditions related to thrombosis, such as deep vein...

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma…

Key Takeaways from the NK Cell Therapy Pipeline Report Key Takeaways from the NK Cell Therapy Pipeline Report Request a sample and discover the recent advances in the NK cell therapy segment @ NK Cell Therapy Pipeline Report The NK cell therapy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage NK cell therapies, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an...

DBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J200), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share,...

Innocan to Direct Full Focus on Following Positive FDA Engagement and…

Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan's non-clinical development plan and Phase I clinical study design for the LPT-CBD's Investigational New Drug (IND) filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA's Center for...

Alkermes to Participate in Two Upcoming Investor Conferences

Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT) Jefferies London Healthcare Conference Date/Time: Tuesday, Nov. 19, 2024 at8:00 a.m. ET( 1:00 p.m. GMT ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has...

VENDEE GLOBE: ALAN ROURA, HUBLOT AND THE WHOLE OF SWITZERLAND READY TO TAKE ON…

A date with the oceans awaits. At 13:02 on Sunday 10th November, Alan Roura will officially be setting off on his third consecutive Vendée Globe aboard the IMOCA Hublot, adding his name and that of the prestigious watch manufacture to the annals of Swiss sporting history! A date with the oceans awaits. At 13:02 on Sunday 10 thNovember,Alan Rourawill officially be setting off on his third consecutive Vendée Globe aboard the IMOCA Hublot, adding his name and that of the prestigious watch...

French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials…

Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug, announced today that it has successfully secured the funding needed to begin Phase 1 clinical trials. The company is slated to begin clinical trials in the U.S. in mid-2025. This crucial funding will enable AdipoPharma to accelerate its clinical development, marking a...

Idorsia is advancing the treatment of hypertension with new data at the 2024…

Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, will be presented at the American Heart Association (AHA) annual Scientific Sessions 2024, taking place in Chicago, Illinois, November 16–18, 2024. AHA Scientific Sessions is the preeminent conference of its kind featuring top global leaders in cardiovascular and brain health...

Whole Genome Sequencing Market to Be Worth $7.17 Billion by 2031 - Exclusive…

Whole Genome sequencing is a method for analyzing entire genome. It determines precise order of every base pair in a genome. Whole genome sequencing provides information about protein coding and non-coding regions. With the advent of next generation sequencing whole genome sequencing have become cheaper, faster and powerful. Whole genome sequencing has wide applications including genetic disease research, cancer research, genotyping and epidemiology. Whole Genome sequencing is a method for...

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCopenhagen, Denmark, November 11, 2024 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares...

Synthetic Biology Market to Hit USD 31.52 Billion by 2029 with 20.6% CAGR |…

Browse in-depth TOC on "Synthetic Biology Market" Browse in-depth TOC on "Synthetic Biology Market" 722 - Tables 46 - Figures 536 - Pages The tool segment is segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms, xeno nucleic acids and synthetic cells. The oligonucleotides & synthetic DNA segment dominated tool segment in terms of market share and CAGR. The large share of this segment is attributed to the rising demand…

Topical Drug Delivery Market is expected to generate a revenue of USD 177.97…

As the demand for localized treatment options continues to rise, topical drug delivery systems are gaining prominence across the pharmaceutical industry. From dermatology to pain management and beyond, this market is witnessing significant advancements, driven by technological innovations and a growing preference for non-invasive treatment methods. As the demand for localized treatment options continues to rise, topical drug delivery systems are gaining prominence across the pharmaceutical…

PathogenDx Applauded by Frost & Sullivan for Enabling Early and Precise UTI…

PathogenDx's D3 Array™-UTI contains molecular probes associated with specific pathogens, and ARG gene markers. Each array has 324 to 576 probes printed in a well. Compared to qPCR assays, the D3 Array-UTI offers greater accuracy, lower costs, and higher throughput. The entire process can complete 48 samples in about 6 to 7 hours. While some competitors can complete their process in 5 hours, they are limited to between 8 and 14 samples. The D3 Array™ provides a greater binding area compared to…

Airdoc is committed to the early screening and predictive analysis of chronic…

AI-FD16H is a fully automatic mydriasis-free fundus camera specially designed and developed for artificial intelligence fundus image analysis. It is non-invasive and suitable for rapid screening, with automatic pupil tracking, positioning, focusing and shooting. The AI seamlessly connects to capture images and conducts real-time analysis. It has high-definition imaging of 12 million pixels and a large field of view of 50°. The nine-point internal fixation covers a wider field of vision. It has a…

Economist Impact's 4th edition Future of Health Asia to empower healthcare…

Healthcare leaders continue to face challenges to mitigate vulnerabilities, manage sustainability, digitise and improve the value of health ecosystems to make them accessible and inclusive. Developments in the field of AI are presenting opportunities and uncertainties. This event brings together more than 300 health leaders to shape the future use of AI. Healthcare leaders continue to face challenges to mitigate vulnerabilities, manage sustainability, digitise and improve the value of health...

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical…

The Phase 2b clinical trial (CTR20231695) was a multicenter, randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the efficacy and safety of bi-weekly (Q2W) and once-weekly (QW) dosing regimens of GZR18 injection. The study enrolled a total of 340 participants, all of whom were obese (BMI≥28 kg/m²) or overweight (BMI≥24 kg/m²) with at least one weight-related comorbidity and whose weight was poorly controlled by diet and exercise. Participants were randomly…

Altri Comunicati